Share

    


In This Section

Home / News & Media / Oncology Newsfeed

Oncology Newsfeed

  • CMS Releases Medicare Part C and Part D Proposed Rule

    On November 26, the Centers for Medicare & Medicaid Services (CMS) announced proposed policies that continue to tackle drug pricing reform. Top-line takeaways from today’s proposals include:

    • Proposed reform to Medicare Part D’s “protected” therapeutic classes.
    • A new requirement in Medicare Part D to allow for increased transparency between patient and provider with provision of out-of-pocket cost obligations for prescription drugs whenever a prescription is written.
    • A continued push to allow for and implement “step therapy” in Medicare Advantage plans for Part B drugs. The proposed rule also states the potential to infuse prior authorizations within this pool as well.
    • Proposed implementation of a “statutory requirement” that would prohibit pharmacy gag clauses in Part D.

    Read the CMS fact sheet on the proposed rule here.
    Read the full proposed rule here.

    The ACCC policy team is continuing to analyze this proposal. Stay tuned for more updates.

    Posted 11/26/2018


  • ACCC Signs Letter of Support for CLINICAL TREATMENT Act

    On November 26, the Association of Community Cancer Centers (ACCC) joined dozens of cancer care organizations and associations in signing a letter of support for H.R. 6836, the CLINICAL TREATMENT Act. This legislation would ensure that states cover routine care costs of participation in approved clinical trials for Medicaid enrollees with life-threatening conditions. Medicaid is currently the only major payer that is not required by federal law to cover these costs.

    Read the full letter of support for H.R. 6836 here.

    Posted 11/26/2018


  • FDA Approves Venetoclax for Acute Myeloid Leukemia

    On November 21, the Food and Drug Administration granted accelerated approval to venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

    Read the full FDA press release here.

    Posted 11/26/18



  • FDA Approves Glasdegib for Acute Myeloid Leukemia

    On November 21, the Food and Drug Administration approved glasdegib (Daurismo, Pfizer Inc.) in combination with low-dose cytarabine (LDAC), for newly-diagnosed acute myeloid leukemia (AML) in patients who are 75 years old or older or who have comorbidities that preclude intensive induction chemotherapy.

    Read the full FDA press release here.

    Posted 11/26/2018


  • ACS Releases Report on Current State of Cancer Screening

    On November 19, the American Cancer Society (ACS) published a report in CA: A Cancer Journal for Clinicians discussing the status of cancer screening and proposing key areas where further attention is needed. ACS highlighted five key focus areas to help cancer screening realize its full potential:
    • Improving the implementation of existing screening modalities
    • Improving the quality and performance of currently available screening tests
    • Developing entirely new screening strategies to screen for cancers currently amenable to screening
    • Developing increasingly refined, risk-based screening strategies
    • Developing effective ways to screen for cancers for which screening tests do not exist.
    Read the full report here.

    Read the ACS press release on the report here.

    Posted 11/19/2018


  • "Feel More Like You" Program to Help Cancer Patients with Physical Changes

    On November 19, Walgreens announced the launch of its "Feel More Like You" program designed to assist people living with cancer manage the physical changes associated with treatment. Formed in collaboration with Look Good, Feel Better and Cancer Support Community, the program will feature trained beauty consultants and pharmacists working together to provide personalized support to individuals with cancers at more than 400 stores across the country.

    Read the full Walgreens press release here.

    Posted 11/19/18


  • FDA Approves Brentuximab Vedotin for Peripheral T-Cell Lymphoma

    On November 16, the U.S. Food and Drug Administration expanded the approved use of brentuximab vedotin (Adcetris, Seattle Genetics) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). This is the first FDA approval for treatment of newly diagnoses PTCL, and the agency used a new review program to complete the approval more quickly.

    Read the full FDA press release here
    .

    Posted 11/16/2018


  • CMS Strengthens Federal Support to Californians Affected by Wildfires

    On November 14, the Centers for Medicare & Medicaid Services (CMS) announced that the agency has taken steps to support California residents displaced and recovering from the wildfires destroying portions of the state.On November 13, Health and Human Services Secretary Alex Azar declared a public health emergency (PHE) in areas of California retroactive to November 8. The PHE allows CMS to waive or modify certain Medicare, Medicaid, and Children’s Health Insurance Program (CHIP) requirements if necessary to provide health services.

    The agency will take the following steps to support the state of California and those residents impacted by wildfires: 

    • Waivers for Skilled Nursing Facilities and Assistance for Hospitals and other Healthcare Facilities: CMS will issue a blanket Skilled Nursing Facility waiver, described on the website below; and the Regional Office will provide numerous technical assistance responses to the state, California Hospital Association and providers on specific types of CMS and other HHS program flexibilities that are available with and without waivers. These program flexibilities and waivers work to provide continued access to care for beneficiaries. For more information on the waivers CMS will grant, visit https://www.cms.gov/Emergency.
    • Special Enrollment Opportunities and Medicare Flexibilities: CMS will be providing beneficiaries affected by the California wildfires an Special Enrollment Period (SEP) that gives them an additional opportunity to add, drop, or change their Medicare health and prescription drug plan in the event they are eligible for an SEP and unable to make an election during the fall open enrollment period or another election period for which they were eligible. For more information on special enrollment periods, visit: https://www.cms.gov/Medicare/Eligibility-and-Enrollment/MedicareMangCareEligEnrol/index.html. When a public health emergency is in effect, Medicare Advantage Organizations in affected areas are required to waive prior authorization and other gatekeeper requirements and to allow care to be provided by non-contracted providers and facilities. In addition, Part D plan sponsors are expected to lift certain limits for drug benefits.
    • Dialysis Care: Dialysis patients who are unable to receive dialysis services at their usual facility and who need assistance to locate a facility where they can be dialyzed, should call the NW 17 (Northern California) Patient Hotline (800.232,3773) or NW 18 (Southern California) Patient Hotline (800.637.4767) for assistance. The following large dialysis organization hotline numbers are also available for patients: DaVita Emergency Dialysis Services (800.400-8331); Fresenius Kidney Care Emergency Hotline (800.626.1297); Dialysis Clinic Inc. (DCI) Emergency Command Center (866.424.1990); and U.S. Renal Care Emergency Hotline (866.671.8772).
    People with federal benefits and providers and suppliers of healthcare equipment and services that have been impacted by the California wildfires are encouraged to seek help by visiting CMS' emergency webpage: http://cms.gov/emergency.

    Posted 11/14/2018


  • CMS to Host November 19 PFS Final Rule Open Call

    On Monday, November 19, from 2:00 to 3:30 PM ET, the Centers for Medicare & Medicaid Services (CMS) will host a call to address three key topics stemming from the finalization of the CY 2019 Physician Fee Schedule (PFS) Final Rule. During this call, CMS experts will briefly cover three provisions and address questions related to:

    • Streamlining Evaluation and Management (E/M) payment and reducing clinician burden
    • Advancing virtual care
    • Continuing to improve the Quality Payment Program to reduce burden and offer flexibilities to help clinicians successfully participate.

    Participants are encouraged to review the final rule prior to the call and the following materials:

    The target audiences for this call are Medicare Part B fee-for-service clinicians; office managers and administrators; state and national associations that represent healthcare providers; and other stakeholders.

    Click here to register for this call and other Medicare Learning Network events.

    Posted 11/14/2018



  • ACCC Releases CY 2019 MPFS and OPPS Final Rule Summaries

    On November 1 and 2, the Centers for Medicare & Medicaid Services (CMS) finalized its CY 2019 Physician Fee Schedule (PFS)/Quality Payment Program (QPP) and Hospital Outpatient Prospective Payment System (OPPS) rules. ACCC has released summaries on these final rules, available for ACCC members here:

    On Wednesday, November 28, join legal experts from Hogan Lovells for a one-hour overview and discussion about the Centers for Medicare & Medicaid Services (CMS) Final CY 2019 OPPS and PFS rules. The agency finalized several significant proposals this year and beyond that will impact payments to Evaluation & Management (E/M) visits, 340B hospitals and outpatient facilities, as well as access for biosimilars and telehealth, and much more.

    Webinar: CMS Final CY 2019 Outpatient Prospective Payment System (OPPS) & Physician Fee Schedule (PFS) Rules: What You Need to Know
    Wednesday, November 28, 2018
    3:30 – 4:30 PM EST
    Register Here (login required)

    Posted 11/13/2018